- Home
- AREB vs PHIO Comparison
AREB vs PHIO Comparison
Compare AREB & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREB
- PHIO
- Stock Information
- Founded
- AREB 2014
- PHIO 2011
- Country
- AREB United States
- PHIO United States
- Employees
- AREB N/A
- PHIO N/A
- Industry
- AREB Plastic Products
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- AREB Industrials
- PHIO Health Care
- Exchange
- AREB Nasdaq
- PHIO Nasdaq
- Market Cap
- AREB 2.7M
- PHIO 2.3M
- IPO Year
- AREB N/A
- PHIO N/A
- Fundamental
- Price
- AREB $2.52
- PHIO $2.21
- Analyst Decision
- AREB
- PHIO Strong Buy
- Analyst Count
- AREB 0
- PHIO 1
- Target Price
- AREB N/A
- PHIO $36.00
- AVG Volume (30 Days)
- AREB 1.8M
- PHIO 41.4K
- Earning Date
- AREB 11-12-2024
- PHIO 11-14-2024
- Dividend Yield
- AREB N/A
- PHIO N/A
- EPS Growth
- AREB N/A
- PHIO N/A
- EPS
- AREB N/A
- PHIO N/A
- Revenue
- AREB $15,454,870.00
- PHIO N/A
- Revenue This Year
- AREB $45.19
- PHIO N/A
- Revenue Next Year
- AREB N/A
- PHIO N/A
- P/E Ratio
- AREB N/A
- PHIO N/A
- Revenue Growth
- AREB N/A
- PHIO N/A
- 52 Week Low
- AREB $1.90
- PHIO $2.17
- 52 Week High
- AREB $9.27
- PHIO $18.81
- Technical
- Relative Strength Index (RSI)
- AREB 41.27
- PHIO 32.01
- Support Level
- AREB $2.76
- PHIO $2.49
- Resistance Level
- AREB $3.33
- PHIO $3.70
- Average True Range (ATR)
- AREB 0.40
- PHIO 0.31
- MACD
- AREB 0.03
- PHIO -0.10
- Stochastic Oscillator
- AREB 12.14
- PHIO 2.75
About AREB American Rebel Holdings Inc.
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic products. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, vault doors, and Others.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.